Home Cart Sign in  
Chemical Structure| 873857-62-6 Chemical Structure| 873857-62-6

Structure of Fidaxomicin
CAS No.: 873857-62-6

Chemical Structure| 873857-62-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Fidaxomicin is a macrocyclic antibiotic drug that inhibits RNA polymerase sigma subunit, and shows selective eradication of pathogenic Clostridium difficile with minimal disruption to the multiple species of bacteria that make up the normal, healthy intestinal flora.

Synonyms: OPT-80; PAR-101; Dificlir

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Fidaxomicin

CAS No. :873857-62-6
Formula : C52H74Cl2O18
M.W : 1058.04
SMILES Code : C/C([C@H](C/C=C/C=C1\CO[C@@H]([C@H]2OC)O[C@@H]([C@H]([C@@H]2O)OC(C3=C(CC)C(Cl)=C(O)C(Cl)=C3O)=O)C)O)=C\[C@H](CC)[C@@H](O[C@@H]([C@H]4O)OC(C)([C@H]([C@@H]4O)OC(C(C)C)=O)C)/C(C)=C/C(C)=C/C[C@@H]([C@@H](C)O)OC1=O
Synonyms :
OPT-80; PAR-101; Dificlir
MDL No. :MFCD27976367

Safety of Fidaxomicin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H361
Precautionary Statements:P201-P202-P264-P270-P281-P301+P312-P308+P313-P330-P405-P501

Related Pathways of Fidaxomicin

DNA

Isoform Comparison

Biological Activity

Description
Fidaxomicin (OPT-80), identified as a macrocyclic antibiotic, acts as a potent inhibitor of RNA polymerase when taken orally. It exhibits a narrow antibacterial spectrum, notably showing strong activity against Clostridium difficile (MIC90=0.12 μg/mL), making it valuable for research into Clostridium difficile infections (CDI)[1].[2].[3].

In Vitro:

Cell Line
Concentration Treated Time Description References
Escherichia coli RNAP σ70 holoenzyme 75 nM Measure RNAP inhibitory activity PMC6205224
Thermus thermophilus RNAP σA holoenzyme 75 nM Measure RNAP inhibitory activity PMC6205224
Mycobacterium tuberculosis RNAP σA holoenzyme 75 nM Measure RNAP inhibitory activity PMC6205224
Escherichia coli RNAP 50 µM Inhibition of RNA synthesis PMC3388026
RAW264.7 mouse macrophages 30 μM 4 hours To study the effect of Fidaxomicin on toxin A-induced TNF-α expression and NF-κB phosphorylation. Results showed that Fidaxomicin dose-dependently inhibited toxin A-induced NF-κB phosphorylation and TNF-α expression. PMC5740352
A549 cells 12.2 ± 3.6 μM (EC50) 48 hours Evaluate the inhibitory effect of Fidaxomicin on ZIKV infection, showing an EC50 value of 12.2 ± 3.6 μM PMC7392643
Huh7 cells 7.7 ± 1.7 μM (EC50) 48 hours Evaluate the inhibitory effect of Fidaxomicin on ZIKV infection, showing an EC50 value of 7.7 ± 1.7 μM PMC7392643
Vero cells 11.7 ± 2.1 μM (EC50) 48 hours Evaluate the inhibitory effect of Fidaxomicin on ZIKV infection, showing an EC50 value of 11.7 ± 2.1 μM PMC7392643
SNB19 cells 6.0 ± 1.0 μM (EC50) 48 hours Evaluate the inhibitory effect of Fidaxomicin on ZIKV infection, showing an EC50 value of 6.0 ± 1.0 μM PMC7392643
Human colonic CCD-18Co fibroblasts 20 μM 6 hours To evaluate the effect of Fidaxomicin on C. difficile toxin A-mediated cell rounding. Results showed that Fidaxomicin partially reduced toxin A-induced cell rounding. PMC4135997
Clostridium difficile ATCC 43255 0.125 μg/mL 72 hours Inhibited sporulation PMC3388029
Clostridium difficile UK-14 0.125 μg/mL 72 hours Inhibited sporulation PMC3388029
NCM460 human colonic epithelial cells 30 μM 8 hours To evaluate the effect of Fidaxomicin on Clostridium difficile toxin A- and B-induced apoptosis. Results showed that Fidaxomicin significantly reduced toxin A- and B-mediated apoptosis. PMC5740352
Clostridium difficile ≤0.001 –1μg/mL To evaluate the antibacterial activity of fidaxomicin against C. difficile, showing an MIC range of ≤0.001 –1μg/mL and an MIC90 of 0.5 μg/mL. PMC3388021

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mycobacterium smegmatis Bacterial strains Disk diffusion method 100 μM, 250 μM, 500 μM Single dose, incubated for 48 hours Evaluate the effect of RbpA mutants on Fdx sensitivity, showing that NTT deletion leads to increased Fdx resistance, while R79A and R88A mutants increase Fdx sensitivity. PMC8956947
Ifnar1−/− mice ZIKV infection model Tail vein injection 20 or 10 mg/kg Once daily for 7 days Evaluate the therapeutic effect of Fidaxomicin on ZIKV-infected mice, showing significant improvement in survival rate and alleviation of pathological damage PMC7392643
Mice Ileal loop model Local administration 20 μM 30 min pretreatment followed by exposure to toxin A for 4 h To evaluate the effect of Fidaxomicin on Clostridium difficile toxin A-mediated intestinal inflammation. Results showed that Fidaxomicin significantly inhibited toxin A-mediated NF-κB phosphorylation and tissue damage. PMC5740352
C57BL/6 mice C. difficile toxin A-induced ileitis model Ileal loop injection 5, 10, or 20 μM Single dose, evaluated after 4 hours To evaluate the effect of Fidaxomicin on C. difficile toxin A-mediated ileal inflammation. Results showed that Fidaxomicin significantly reduced toxin A-induced tissue damage, IL-1β expression, and ERK phosphorylation. PMC4135997

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04070352 Clostridium Difficile Infectio... More >>n (CDI) Less << WITHDRAWN 2023-05-01 UPMC, Pittsburgh, Pennsylvania... More >>, 15213, United States Less <<
NCT02395848 Clostridium Difficile Infectio... More >>n Less << PHASE3 TERMINATED 2021-08-30 Christine Lee, Victoria, BC - ... More >>British Columbia, V8R 6CT, Canada Less <<
NCT00097422 Diarrhea PHASE2 COMPLETED 2005-04-01 Advanced Biologics, New Hope, ... More >>Pennsylvania, 18938, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

0.95mL

0.19mL

0.09mL

4.73mL

0.95mL

0.47mL

9.45mL

1.89mL

0.95mL

References

 

Historical Records

Categories